Search | Clinical Trials Finder

Conditions: Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Hypertension, Eclampsia, Gestational Hypertension, Cardiovascular Diseases, Toxemia, Pregnancy Complications, Vascular Diseases, Hypertension, Pregnancy Induced, Hypertension;Pre-Eclamptic
Interventions: Usual care, Tight blood pressure control; Drug
Lead sponsor: Alisse Hauspurg; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Omada Hypertension Program; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Hypertension
Interventions: OWL-Hypertension 8 Wk Trial; Behavioral
Lead sponsor: Paula Gardiner; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions: Amlodipine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions: Prostaglandin Analog, Timolol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertension
Interventions: text message medication reminders; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pulmonary Arterial Hypertension
Interventions: Sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 11
States / cities: Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Primary Open-angle Glaucoma
Interventions: Patient Educational Intervention, Usual Care, Ophthalmologist Educational Intervention; Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years to 90 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Pulmonary
Interventions: sildenafil, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 24
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more

Conditions: Arterial Hypertension, Atrial Fibrillation
Interventions: Circumferential PV isolation, PV isolation+renal denervation; Procedure
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation; Network
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Compartment Syndromes
Interventions: Percutaneous catheter drainage; Procedure
Lead sponsor: Orlando Regional Medical Center; Other
Eligibility: 15 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Chronic Thromboembolic Pulmonary Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more

Conditions: Hypertension
Interventions: Patient educational letter to engage provider in hypertension rx discussion, Financial incentive (Arms B and C) and health educator phone call (Arm C); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Iowa City, Iowa • Minneapolis, Minnesota

Conditions: Pulmonary Arterial Hypertension
Interventions: Imatinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Sickle Cell Disease, Pulmonary Hypertension
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 12 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Oakland, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Hypertension
Interventions: Disclosure of adherence report to clinician, MedSignals pillbox; Behavioral · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Failure, Medication Adherence, Hypertension
Interventions: mHealth; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypertension, Resistant to Conventional Therapy, Atrial Fibrillation
Interventions: Circumferential PV isolation, Circumferential PVI+renal denervation; Procedure
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation; Network
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions: Direct Selective Laser Trabeculoplasty (DSLT); Device
Lead sponsor: Ngoc Nguyen Inc.; Other
Eligibility: 20 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Jose, California

Conditions: Orthostatic Hypotension
Interventions: Droxidopa, Pyridostigmine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glaucoma
Interventions: NT-501, Sham comparator; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertension, Pulmonary
Interventions: PF-00489791, placebo, sildenafil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Phoenix, Arizona • Gainesville, Florida • Omaha, Nebraska + 2 more

Conditions: Hypertension, Heart Failure
Interventions: Clevidipine, Standard of Care IV antihypertensive; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 9
States / cities: Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more

Search by objective public record fields.

Optimal Blood Pressure Treatment Thresholds Postpartum

Remote Patient Monitoring and Health Coaching vs. Usual Care for the Treatment of Hypertension

Reducing Disparities in the Treatment of Hypertension Using the OWL mHealth Tool

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

Text Messaging to Improve Hypertension Medication Adherence in African Americans

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

Combined Treatment of Arterial Hypertension and Atrial Fibrillation

Percutaneous Catheter Decompression in the Treatment of Elevated Intra-abdominal Pressure

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Implementing Evidence Based Treatment of Hypertension

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease

Measuring Adherence to Control Hypertension

Adherence Enhancement for Renal Transplant Patients

Combined Treatment of Resistant Hypertension and Atrial Fibrillation

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

Droxidopa / Pyridostigmine in Orthostatic Hypotension

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)